BioMarin Pharma (BMRN) reported Q4 EPS of $0.00, which may not compare to the analyst estimate of ($0.06). Revenue for the quarter came in at $537.5 million versus the consensus estimate of $537.62 million.
GUIDANCE:
BioMarin Pharma sees FY2023 EPS of $1.80-$2.05, versus the consensus of $1.61. BioMarin Pharma sees FY2023 revenue of $2.375-2.5 billion, versus the consensus of $2.58 billion.